Evidence map›Paper›PMID 41944209›Full record

ArticleCancer science2026

ROWVA: A Structure-Based Metric for Predicting the Pathogenicity of Protein Variants Using Alphafold2.

Taiki Furutani, Yuka Okusha, Hiroki Nagami, Hiroko Hanafusa, Shuta Tomida, Ryusuke Sawada, Yasuyuki Hosono, Masahiro Nakatochi

Abstract read
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Taiki FurutaniPublic Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuka OkushaDepartment of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Hiroki NagamiDepartment of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Hiroko HanafusaDepartment of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Shuta TomidaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0003-3786-936X
Ryusuke SawadaDepartment of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Yasuyuki HosonoDepartment of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Masahiro NakatochiPublic Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-1838-4837

Funding

Japan Agency for Medical Research and Development JP21wm0425013Japan Agency for Medical Research and Development JP23kk0305020Japan Agency for Medical Research and Development JP24wm0625301Japan Agency for Medical Research and Development JP25ama221612Japan Society for the Promotion of Science 22H03350Japan Society for the Promotion of Science 22H04923
6 · The paper itself

Abstract

p53, an important tumor suppressor protein, functions as a tetramer. Therefore, malignant variants in the tetramer-forming domain increase the likelihood of p53 dysfunction. Recent developments in genome analysis technology have expanded our understanding of malignant variants. However, variants of uncertain significance are also being increasingly identified. Hence, methods to assess the pathogenicity of these variants are required. In this study, we aimed to examine whether AlphaFold2 can be used to evaluate the functional impacts of p53 variants based on predicted three-dimensional (3D) structural information. For each variant present in datasets of p53 functional score, we performed 3D structural prediction using AlphaFold2. We analyzed the correlations among multiple AlphaFold2-derived scores to predict functional scores, such as protein stability and pathogenicity labels, for each dataset. The root-mean-square deviation obtained by comparing the 3D structures predicted by AlphaFold2 for the wild-type and variant structures showed a high correlation with each functional score. Overall, these findings indicate that AlphaFold2 can be used to evaluate variants.

Indexed as

Tumor Suppressor Protein p53Genetic VariationHumansModels, MolecularProtein ConformationProtein StabilityTumor Suppressor Protein p533D protein structural predictionAlphaFold2p53tumor suppressorvariants of uncertain significance

Identifiers

PMID41944209
PMCPMC13580829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.